25 LLC’s Kiniksa Pharmaceuticals KNSA Stock Holding History

25 LLC’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-36	Closed	-$501	–	295
2023 Q2	$501	Buy	+36	New	+$482	﹤0.01%	539

Other funds holding KNSA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

25 LLC's KNSA Position: Q3 2023 in Review

25 LLC sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2023, closing a stake of 36 shares — an estimated $501 sold.

25 LLC first reported a position in KNSA in Q2 2023 and held it in 1 quarter. The position peaked at $501 in Q2 2023. 134 funds tracked by Wall St. Rank hold KNSA as of Q3 2023.

25 LLC reported no remaining Kiniksa Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
25 LLC sold 36 Kiniksa Pharmaceuticals shares in Q3 2023, an estimated $501.
25 LLC first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and held it in 1 quarter.
25 LLC's Kiniksa Pharmaceuticals position peaked at $501 in Q2 2023.
134 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.